Saturday 17 October 2026
Export NEUP’s income statement to Excel — free account
Neuphoria Therapeutics Inc.
NEUP Healthcare Biotechnology
Neuphoria Therapeutics Inc.’s revenue for fiscal 2026 (year ended June 2026) was $1.2 million, down 92.5% from fiscal 2025. In the quarter to June 2026, revenue fell 107.3%, EPS grew 83.6% and free cash flow grew 133.9%, each against the same quarter a year earlier.
3.30
0.01
−0.30%
Follow NEUP
Neuphoria Therapeutics Inc. (NEUP) P/E ratio
Neuphoria Therapeutics Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 3.4× (June 2025) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2026 | 0.0× | — |
| FY2025 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2025 | 0.0× | — |
| Mar 2025 | 2.7× | — |
| Dec 2024 | 0.0× | — |
| Jun 2023 | 0.0× | — |
| 5 more quarters | Free account |
Against its own ten years
Low 0.0×
High 3.4×
Ten-year median
0.0×
Current reading's percentile
95
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| DYAI Dyadic International Inc. compare | n/m |
| NEUP Neuphoria Therapeutics Inc. | n/m |
| JSPR Jasper Therapeutics, Inc. compare | n/m |
| TCRX TScan Therapeutics, Inc. compare | n/m |
| ACGN Aceragen, Inc. compare | n/m |
| ANEB Anebulo Pharmaceuticals, Inc. compare | n/m |
| ATYR aTyr Pharma, Inc. compare | n/m |
| PBM Psyence Biomedical Ltd. compare | 0.2× |
| RADX Radiopharm Theranostics Limited - Sponsored ADR compare | — |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)